Lysando

Lysando AG is a private, pre-revenue biotech company based in Helsinki, Finland, pioneering a novel approach to antibacterial therapy. The company's platform centers on Artilysin®, a targeted protein technology engineered to kill harmful bacteria, including antibiotic-resistant strains, without damaging the patient's protective microbiome. This positions Lysando at the intersection of the urgent global antimicrobial resistance (AMR) crisis and the growing field of microbiome therapeutics. The company's stated philosophy prioritizes people over profits, aiming to develop treatments that preserve natural health.

Artilysin® platform: Engineered bacteriophage-derived enzymatic proteins (endolysins) that specifically target and lyse pathogenic bacteria while aiming to preserve the beneficial human microbiome.

Lysando competes in the novel antimicrobial space against companies developing phage therapies, narrow-spectrum antibiotics, and other microbiome-modulating therapies. It also indirectly competes with traditional antibiotic developers and large pharmaceutical companies with infection portfolios. Its key differentiation is the targeted, enzymatic mechanism designed explicitly for microbiome preservation.